Cetrorelix is a GnRH antagonist. It is filed in this library under sexual & reproductive, a navigation topic rather than a statement of where it acts. As a regulatory matter it has at least one product approved by the FDA.
Regulatory status
Cetrorelix has an FDA-approved product on the U.S. market, marketed as Cetrorelix Acetate under application ANDA218150.
The current label is held by Gland Pharma Limited.
From the FDA label
INDICATIONS AND USAGE Cetrorelix acetate for injection is indicated for the inhibition of premature LH surges in women undergoing controlled ovarian stimulation..Quoted from the FDA-approved prescribing information
The evidence
2 sources on Cetrorelix published between 2000 and 2016, each resolved to its journal of record. Titles are listed so you can judge the evidence rather than take a summary on trust.
Nearby
Markers on this pathway
Cetrorelix's FDA-approved label indicates it for a condition managed by suppressing or controlling gonadotropin release. These are the markers clinicians use when assessing the pituitary-gonadal axis. They are listed here so you can read about them, not as a statement that Cetrorelix changes any of them.
A 60-second questionnaire, reviewed by a U.S.-licensed physician.
Find my protocolEducational reference only. This page explains what has been published about Cetrorelix. It is not medical advice, it is not a diagnosis, and it carries no dosing information of any kind. OPTML does not offer or supply this compound unless a product page on this site says otherwise.
Treatment decisions are made by a licensed physician after an individual evaluation. Compounded preparations are not FDA-approved or evaluated by the FDA for safety, effectiveness, or quality. Individual results vary.
All 150 peptides